The main objective of this paper is to investigate the pharmacokinetics of NM394 (an active metabolite of prulifloxacin) and evaluate the dose relationship and accumulation characteristics after single and multiple doses of prulifloxacin. Thirty healthy volunteers were given 132 mg, 264 mg, and 528 mg of prulifloxacin capsules in a randomized test corresponding to low, medium and high groups for single dose trial. With one-week washout period, 264 mg of prulifloxacin capsules were given to eight volunteers of the medium group for multiple doses trial. The concentration of NM394 in serum was determined by a sensitive HPLC method and its pharmacokinetic parameters were analyzed by DAS2.0.1 and evaluated by SPSS statistic software (version 13.0). Various parameters were determined. Numerical experiments show that the pharmacokinetic parameters of NM394 displayed first order linear pharmacokinetic character. There are no big differences in pharmacokinetic characteristics of NM394 between single and multiple doses. Almost no significant accumulation of drugs is observed after multiple doses of 264 mg per day for 7 d and chronopharmacokinetics were first observed.
INTRODUCTION
Prulifloxacin, [(±)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1, 3-dioxolen-4-yl) methyl-1-piperazinyl] -4-oxo-4H- [1, 3] thiazeto [3, 2-α] quinoline-3-carboxylic acid], a new broad-spectrum fluoroquinolone antibacterial, is the prodrug of ulifloxacin which is rapidly metabolized into its active noumenon after oral administration and intestinal absorption, NM394 [(±)-6-fluoro-1-methyl-4-oxo-7-1-piperazinyl -4H- [1, 3] thiazeto [3, 2-α] quinoline-3-carboxylic acid]. NM394 possesses potent antibacterial activity against both gram-positive and gram-negative bacteria with a wide antibacterial spectrum and particularly strong activity [1] .
Till now, different analytical methods have been developed for determining the concentration of NM394 in plasma including HPLC [2] , LC-MS/MS [3] . As reversed-phase liquid chromatography (LC) is often preferred in common laboratories, therefore, in this paper, a HPLC method with ultraviolet detector for analysis of NM394 in serum was developed and its pharmacokinetic characteristics, dose relationship and drug accumulation after single dose and multiple doses of prulifloxacin capsules in healthy Chinese volunteers were evaluated.
MATERIALS AND METHOD 2.1. Apparatus and Chemicals
Waters 2690 HPLC with 996 Photodiode Array Dectector (Waters, U.S.A.), the column is Platilsil ODS C 18 (150 × 4.6 mm, 5 µm, Dikma, China) with a guard column of Dikma Easy Guard C18 (8 × 4 mm, 5 µm, Dikma, China).
NM394 reference (97.5% purity, batch no. SSC-A04-20071223) was got from Hunan Huana Tiandi Pharmaceutical Company, Ltd., Fleroxacin (IS, batch no. 130458-200301) was purchased from National Institute for the Control of Pharmaceutical and Biological Products, Prulifloxacin capsule (batch no. 080301, 132 mg per capsule, equivalent to 100 mg of NM394) was provided by Sichuan AoBang Pharmaceutical Co. Ltd. (Sichuan, China). HPLC grade acetonitrile was purchased from Fisher Chemicals (New Jersey, U.S.A.), the other reagents were analytical grade.
Assay Method
0.03 mL fleroxacin (12.0 mg · L −1 , IS), 0.4 mL methanol: acetonitrile (1:1) were added into 0.2 mL serum samples (or with NM394 standard solution) and vortexed for 2 min, centrifuged at 13000 rpm for 6 min. The supernatant was transferred to a glass tube and extracted the impurity with Hexane (3 mL) and ethyl acetate (2 mL) for 30 s respectively, the mixture was then centrifuged at 2200 rpm for 4 min (4°C) The supernatant was waived and 30 µL of the lower phase was injected for analysis with mobile phase of acetonitrile and 0.02 mol·L −1 KH 2 PO 4 (containing 0.5% triethylamine and 0.32% phosphoric acid)(10:40.5, V/V) at a flow rate of 1 mL·min -1 . NM394 and IS were separated with Platilsil ODS C18 column (150 × 4.6 mm, 5 µm) with guard column of Dikma Easy Guard C18 column (8 × 4 mm, 5 µm) at 35°C.
Pharmacokinetics Study
This study was performed according to the rules of Good Clinical Practice. The protocol of this study was approved by Ethical Committee of Sichuan Academy of Medical Sciences & Sichuan Provcinal People's Hospital. A total of 30 healthy volunteers, 15 females and 15 males, were judged to be in good health through medical history review, physical examination and routine laboratory tests. Written informed consent was obtained from each volunteer after detailed verbal and written information on the objective and the possible risks of the study. All subjects avoided using other drugs for at least 2 weeks prior to the study and until its completion. They also were abstained from alcoholic beverages and xanthine-containing foods 48 h prior to each dosing and until the collection of the last blood sample.
The study was an open, randomized, parallel, two-period trial with a oneweek washout period.
30 healthy Chinese volunteers were randomly designed into three dose groups of 132 mg, 264 mg and 528 mg. Aliquots of blood were collected before (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h after orally administered amount of prulifloxacin capsules. Blood samples were centrifuged at 2500 rpm for 8 min and serum was collected and stored at -70°C for analysis.
With a one-week washout period, 8 volunteers (4 males and 4 females) of the medium dose group were administered for multiple doses according to the following plan: the same volunteers were orally given 264 mg prulifloxacin capsules twice a day at 8:00 am and 8:00 pm for 6 days, and the last 264 mg prulifloxacin capsules were administered at 8:00 am on the 7th day. Aliquots of blood were collected at 8:00 am and 8:00 pm before dosing of 5th, 6th, before (0 h) and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 36 h of the 7th day after 264 mg prulifloxacin capsules administration.
Pharmacokinetics Analysis
The peak serum concentration (C max ) and the time reach to C max (T max ) were obtained directly from individual serum concentration-time curves. The NM394 serum concentration-time data after single dose and multiple doses, expressed as mean ± SD, were analyzed with the aid of DAS 2.0.1 software.
The relationship and comparisons of the main pharmacokinetic parameters of NM394 were statistically analyzed by SPSS13.0 software. Data were deemed statistically significant when the two-side P values were lower than 0.05 (P < 0.05).
RESULTS AND DISCUSSION

Results of Method Validation
The retention time of NM394 and IS were 5.6 min and 3.9 min respectively. The assay was linear in the range of 0.0195-5.0018 mg·L −1 . The lower limit of quantization was 0.0195 mgL −1 . The intra-precision of 0.048, 1.2012 and 4.1824 mg·L −1 were 5.48%, 4.49% and 1.19% and the inter-day precision were 4.86%, 4.64% and 2.25%, respectively. The accuracy of 0.048, 1.2012 and 4.1824 mg·L −1 were 99.54%, 99.42% and 101.13% respectively. The stability of samples in different storing conditions meets the request for assay.
Pharmacokinetic Parameters of Single Dose Administration
The serum profiles of NM394 after single oral dose of 132 mg, 264 mg and 528 mg prulifloxacin capsules are shown in Fig. 1 Fig. 1 also showed that T max increasing with dose indicated dose-dependence in rate (not extent) of absorption without significant difference, which caused C max was not proportionally increased.
Pharmacokinetic Parameters of Multiple Doses
In clinical treatment of some diseases, antibacterial activity can't be performed by single dose administration of prulifloxacin, so multiple doses is necessary. Recommended usage of the amount is 264 mg prulifloxacin capsules, b.i.d. for 7~10 days. Pharmacokinetic characters of multiple doses were investigated by simulating clinical therapy. The serum profiles of NM394 after single dose and multiple doses of 264mg prulifloxacin capsules are shown in Fig. 2 and its pharmacokinetic parameters are listed in Tab. 2. Steady state was confirmed based on the trough serum concentrations at 48 h, 36 h, 24 h, 12 h and o h before full pharmacokinetic sampling in multiple dose period. The mean C ss-min of NM394 at 8:00 am on 5th, 6th and 7th day was 0.352, 0.377 and 0.404 mg·L -1 , respectively, which relative standard deviation was 6.90%. So steady state was achieved after orally 264 mg prulifloxacin capsules twice a day for 6 days. However, the mean C ss-min of NM394 at 8:00pm on 5th, 6th and 7th day was 0.249, 0.228 and 0.291 mg·L -1 , respectively, which relative standard deviation was 12.42%. The mean C ss-min at 8:00 am is increased by 47.5% comparing to that of the evening. The statistical analysis between the morning and the evening steady state minimum concentration of NM394 after multiple doses was got with Paired-Samples t test, and the result showed there was significant difference (p = 0.000). Indeed, such a phenomenon may be seen in all of the individual profiles shown in Figure 3 . Today, a vast amount of literature clearly documents that many human physiological functions are not constant, but highly variable in a predictable-intime manner as expressed by prominent rhythms of various period, such as cardiovascular, pulmonary, hepatic, and renal function. Daily variations in physiological functions can influence drug absorption, distribution, metabolism and elimination [7] . The previous study showed that food had no effect on C max , AUC and excretion of NM394 [6] , the influence of food on the absorption of NM394 was then excluded. Combining these findings, the significant difference between the morning and the evening C ss-min might be explained as a chronopharmacokinetic phenomenon.
Pharmacokinetics of Oral Prulifloxacin Capsules in Healthy Volunteers
Comparison of the main pharmacokinetic parameters between single and multiple doses using Paired-samples t test gave the following results. There was no significant difference for the main pharmacokinetic parameters after multiple doses. However, there is significant difference (p = 0.000) between AUC (0-∞) of single dose and AUC (0-36h) of multiple doses, and it indicated that there is a slightly accumulation of C max of NM394 after multiple doses (but no significant difference).
Sex-Related Difference
Independent-sample t test was used to compare the main pharmacokinetic parameters of NM394 between males and females after single and multiple doses. The results showed that there was no significant difference of the main No. 5
No. 6
No. 7
No. 8 phamacokinetic parameters of NM394 between male and female after single and multiple doses except for AUC (0-36h) , AUC (0-∞) and CL/F in 264 mg group and 528mg group and C max in 528 mg group.
CONCLUSION
Prulifloxacin is the prodrug of NM394 which is used for some refractory infectious diseases, such as urinary tract infections and respiratory tract infections. Since prulifloxacin was rapidly hydrolyzed after administration, its active metabolite, NM394, was used for prulifloxacin pharmacokinetic study.
The results of NM394 after single and multiple doses showed that its pharmacokinetic behavior could be fitted by an open two-compartment model and displayed first order linear pharmacokinetic character which is almost consist with the previous studies [3] [4] [5] . The slightly accumulation of C max of NM394 after multiple doses (but no significant difference) indicated that the plan of twice a day for administration is safe.
The significant difference between the morning and the evening C ss-min might be explained as a chronopharmacokinetic phenomenon. As no enough data of concentration-time profiles for night of NM394 and no supporting evidence from references, the chronopharmacokinetic phenomenon needs to be further proved.
